Published in World J Gastroenterol on September 14, 2012
Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (2008) 6.35
Natural history of early primary biliary cirrhosis. Lancet (1996) 3.24
Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol (2003) 2.69
Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology (2004) 2.64
Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology (2005) 2.15
Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology (2007) 2.08
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology (2006) 1.96
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology (2005) 1.67
The role of environmental factors in primary biliary cirrhosis. Trends Immunol (2009) 1.61
High prevalence of seroimmunologic abnormalities in relatives of patients with active chronic hepatitis or primary biliary cirrhosis. N Engl J Med (1974) 1.56
Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology (2000) 1.55
Mitochondrial and other tissue antibodies in relatives of patients with primary biliary cirrhosis. Clin Exp Immunol (1972) 1.50
Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture. J Gastroenterol (2004) 1.48
Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology (2007) 1.39
Familial primary biliary cirrhosis reassessed: a geographically-based population study. J Hepatol (1999) 1.36
Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology (1987) 1.32
Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int J Epidemiol (1997) 1.27
Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev (2003) 1.23
Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology (2006) 1.15
Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM (2004) 1.13
Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis (2005) 1.10
M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol (1993) 1.07
Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut (2005) 1.07
Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol (2004) 1.06
Characterization of antimitochondrial antibodies in health adults. Hepatology (1998) 1.01
Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology (2004) 1.01
Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut (1995) 0.98
Etiopathogenesis of primary biliary cirrhosis. World J Gastroenterol (2008) 0.96
PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol (2009) 0.93
Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol (2007) 0.93
Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. Clin Immunol (2006) 0.91
Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol (1994) 0.91
Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. J Autoimmun (2005) 0.89
Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol (2002) 0.89
Familial primary biliary cirrhosis. J Hepatol (1994) 0.89
Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med (2002) 0.87
Prevalence of familial disease in primary biliary cirrhosis in Italy. J Hepatol (1997) 0.87
Primary biliary cirrhosis: one disease with many faces. Isr Med Assoc J (2011) 0.86
A study of antimitochondrial antibodies in a random population in Estonia. Am J Gastroenterol (1997) 0.86
Molecular diagnostics of primary biliary cirrhosis. Expert Opin Med Diagn (2008) 0.86
Antinuclear antibodies as ancillary markers in primary biliary cirrhosis. Expert Rev Mol Diagn (2012) 0.85
Presentation and diagnosis of primary biliary cirrhosis in the 21st century. Clin Liver Dis (2008) 0.84
Familial primary biliary cirrhosis in Hiroshima. J Autoimmun (1999) 0.84
Characterization of M2 antibodies in asymptomatic Chinese population. World J Gastroenterol (2003) 0.83
Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol (2006) 0.82
Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology (1992) 0.82
Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol (2003) 0.81
Small ubiquitin-related modifiers: A novel and independent class of autoantigens in primary biliary cirrhosis. Hepatology (2005) 0.81
Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis. J Gastroenterol Hepatol (2004) 0.79
Familial clustering and genetic background of primary biliary cirrhosis in Japan. Dig Dis Sci (2009) 0.77
Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (2008) 6.35
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver Int (2008) 1.76
Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol (2011) 1.56
Emergence of Escherichia coli sequence type 410 (ST410) with KPC-2 β-lactamase. Int J Antimicrob Agents (2012) 1.16
Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis (2013) 1.16
Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev (2011) 1.14
Hodgkin's disease presenting as cholestatic hepatitis with prominent ductal injury. Eur J Gastroenterol Hepatol (2002) 1.14
PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun (2010) 1.13
Spontaneous spondylodiscitis: presentation, risk factors, diagnosis, management, and outcome. Int J Infect Dis (2008) 1.12
Use of TNFα antagonists in refractory AIH: revealing the unforeseen. J Hepatol (2013) 1.07
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology (2014) 1.04
The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. J Autoimmune Dis (2007) 1.02
Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int (2011) 0.99
Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int (2007) 0.96
Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int (2009) 0.96
Autoimmune thyroiditis associated with autoimmune hepatitis. Thyroid (2005) 0.95
Ciprofloxacin-resistant Escherichia coli in Central Greece: mechanisms of resistance and molecular identification. BMC Infect Dis (2012) 0.95
Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis (2004) 0.94
Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol (2007) 0.93
Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. Autoimmun Rev (2012) 0.92
Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. World J Gastroenterol (2010) 0.92
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol (2012) 0.92
The performance of serum inflammatory markers for the diagnosis and follow-up of patients with osteomyelitis. Int J Low Extrem Wounds (2013) 0.91
Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. Clin Immunol (2006) 0.91
IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol (2008) 0.91
Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology (2007) 0.90
Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. Antivir Ther (2011) 0.89
Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol (2002) 0.89
Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases. Clin Diagn Lab Immunol (2005) 0.88
Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease. Clin Exp Med (2013) 0.88
Unusual cardiovascular complications of brucellosis presenting in two men: two case reports and a review of the literature. J Med Case Rep (2011) 0.88
Safety and efficacy of transcatheter arterial chemoemboliazation in the real-life management of unresectable hepatocellular carcinoma. Hepat Mon (2013) 0.88
Ocular disorders as the prevailing manifestations of antiphospholipid syndrome: a case series. Cases J (2009) 0.87
HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. J Clin Virol (2005) 0.87
Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver Int (2011) 0.86
Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C. Am J Gastroenterol (2008) 0.86
Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece. Eur J Intern Med (2008) 0.86
Molecular diagnostics of primary biliary cirrhosis. Expert Opin Med Diagn (2008) 0.86
Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta (2007) 0.86
Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses. Pathol Oncol Res (2008) 0.85
Sleep apnoea syndrome and early stage cirrhosis: a pilot study. Eur J Gastroenterol Hepatol (2006) 0.85
HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int (2012) 0.85
Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. Clin Dev Immunol (2012) 0.85
Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? Dig Liver Dis (2010) 0.85
Improvement in cardiovascular indices after Roux-en-Y gastric bypass or sleeve gastrectomy for morbid obesity. Obes Surg (2013) 0.84
Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun (2005) 0.84
Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. World J Hepatol (2013) 0.84
Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas. Lung Cancer (2008) 0.84
Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity (2013) 0.84
Primary biliary cirrhosis and Henoch-Schonlein purpura: report of two cases and review of the literature. Liver Int (2007) 0.83
IgA antibodies against deamidated gliadin peptides in patients with chronic liver diseases. Clin Chim Acta (2012) 0.82
Hepatitis B re-activation with rituximab therapy: treat the patient not the disease. Liver Int (2011) 0.82
Severe pharyngitis in stockbreeders: an unusual presentation of brucellosis. Occup Med (Lond) (2008) 0.82
Validated analysis of HIF-1alpha expression in cancer cells using a controlled and comparative immunoassay. Oncol Rep (2010) 0.82